ArticleScientific reports2025
Therapeutic thrombocytapheresis short-term efficacy and hematologic impact: comparing MNC procedure of COBE spectra and PLT-5d C5L procedure of COM.TEC.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the disruption in the supply of consumables for platelet separation on the COBE Spectra blood component separator in China, we have performed therapeutic thrombocytapheresis using its mononuclear cell collection procedure (MNC procedure) and compared it with the therapy by COM.TEC platelet donation procedure to compare the influence on patient blood cell indicators. Therapeutic thrombocytapheresis was conducted 69 and 35 times on 38 and 15 clonal thrombocytosis patients using the MNC procedure with the COBE Spectra (MNC group) and the PLT-5d C5L procedure of the COM.TEC platelet donation package (PLT-5d C5L group), respectively. In the MNC and PLT-5d C5L groups, the therapy durations and the processed blood volumes were similar: platelet removal rates, 60.56% (53.59-75.81%) and (84.95 ± 39.46)% (z = 3.017, p < 0.01); white blood cell (WBC) loss values, 2.85 (2.02-3.83) × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.